Pharma & Biotech

Add to MyProactive

Recce Pharmaceuticals secures A$30M debt facility to fund Phase 3...

Recce Pharmaceuticals Ltd has secured a non-dilutive debt facility of up to A$30 million (US$20 million)...

Tetratherix Ltd launches $25 million IPO to fund biotech innovation in tissue healing

Tetratherix launches $25 million IPO to fund biotech innovation in...

17 hours, 27 minutes ago

Recce Pharmaceuticals Ltd - Recce secures A$30 million debt facility from Avenue Capital to support Phase 3 trials

Recce secures A$30 million debt facility from Avenue Capital to...

20 hours, 11 minutes ago

Recce Pharmaceuticals Ltd

Recce Pharmaceuticals tackling antibiotic-resistant ‘superbugs’...

20 hours, 11 minutes ago

Cochlear downgrades FY25 earnings guidance, unveils smart cochlear implant system

Cochlear downgrades FY25 earnings guidance, unveils smart cochlear...

5 days, 18 hours ago

Monash IVF Group Ltd - Monash IVF CEO resigns amid embryo mix-up scandals as calls for IVF regulation grow

Monash IVF CEO resigns amid embryo mix-up scandals as calls for IVF regulation grow

5 days, 19 hours ago

Monash IVF Group Ltd - Monash IVF shares hit by second embryo mix-up incident

Monash IVF shares hit by second embryo mix-up incident

6 days, 15 hours ago

Prescient Therapeutics Ltd - Prescient Therapeutics: Advancing cancer treatment with PTX-100 and cell therapies

Prescient Therapeutics: Advancing cancer treatment with PTX-100 and cell therapies

6 days, 21 hours ago

cancer cell

Prescient Therapeutics seeks to provide new tools for clinicians in combating cancer

6 days, 21 hours ago

Anteris Technologies Pty Ltd - Anteris appoints new directors and confirms board transition

Anteris appoints new directors and confirms board transition

1 week, 1 day ago

Imugene Ltd -

Imugene's CMO John Byon on latest cancer trial data

1 week, 5 days ago

Imugene Ltd

Imugene seeks to activate immune system of cancer patients to identify and eradicate tumours

1 week, 5 days ago

Imugene CMO and CEO talk trial momentum and immuno-oncology progress

Imugene CMO and CEO talk trial momentum and immuno-oncology progress

2 weeks ago

Recce Pharmaceuticals Ltd - Recce Pharmaceuticals completes shortfall placement to raise $7.4 million

Recce Pharmaceuticals completes shortfall placement to raise $7.4 million

2 weeks, 1 day ago

Race Oncology Ltd - Race to engage investors with June showcase and Brisbane briefing

Race to engage investors with June showcase and Brisbane briefing

2 weeks, 2 days ago

Race Oncology Ltd - Race Oncology targets multiple cancer indications as it advances Zantrene

Race Oncology progressing a robust pipeline of clinical activities for bisantrene

2 weeks, 2 days ago

Orthocell Ltd - Orthocell CEO Paul Anderson named finalist in 2025 EY Entrepreneur Of The Year awards

Orthocell CEO Paul Anderson named finalist in 2025 EY Entrepreneur Of The Year awards

2 weeks, 2 days ago

Imugene Ltd - Imugene activates Australian site for Phase II bowel cancer vaccine trial

Imugene activates Australian site for Phase II bowel cancer vaccine trial

2 weeks, 2 days ago

Prescient Therapeutics Ltd -

Prescient begins PTX-100 Phase 2 Trial for rare lymphoma

2 weeks, 5 days ago

Recce Pharmaceuticals Ltd -

China patent boost for Recce's antibacterial pipeline

2 weeks, 5 days ago